1. Introduction
===============

Sulfonylureas have been used in pharmacotherapy since the 1950s when the first antidiabetic compound *carbutamide* was released to the market. Since then, several sulfonylureas have been commonly used as antihypoglycemic (e.g., *tolbutamide*, *glipizide*, *glimepiride*), diuretics (*torasemide*) or herbicides (*rimsulfuron*). Large numbers of sulfonylurea derivatives have also been tested in preclinical studies among others towards histamine H~3~ receptor antagonism \[[@B1-molecules-20-12029],[@B2-molecules-20-12029]\], thromboxane A~2~ receptor antagonism \[[@B3-molecules-20-12029],[@B4-molecules-20-12029]\], antibacterial \[[@B5-molecules-20-12029]\], antimalarial \[[@B6-molecules-20-12029]\] or antifungal activity \[[@B7-molecules-20-12029]\], and in particular, an important part of this research concerns antitumor activity \[[@B8-molecules-20-12029],[@B9-molecules-20-12029],[@B10-molecules-20-12029],[@B11-molecules-20-12029],[@B12-molecules-20-12029]\].

Studies on the antineoplastic activity led to discovery of *N*^1^,*N*^3^-diarylsulfonylureas (DSUs): LY-181984, LY-186641 (*sulofenur*) and LY-295501 ([Figure 1](#molecules-20-12029-f001){ref-type="fig"}) which were recognized as a group of compounds with activity against a broad spectrum of syngeneic rodent solid tumors and human tumor xenografts \[[@B13-molecules-20-12029]\].

![Anticancer diarylsulfonylureas (DSUs).](molecules-20-12029-g001){#molecules-20-12029-f001}

Due to the high *in vivo* activity in mouse models, *sulofenur* and LY-295501 have been evaluated in phase I or II clinical trials on patients with a non-small cell lung carcinoma (NSCLC), renal carcinoma. melanoma, and ovarian cancer \[[@B14-molecules-20-12029]\]. Despite the disappointing results of the tests, mainly due to high hemotoxicity, novel sulfonylurea derivatives with anticancer activity are constantly being developed \[[@B15-molecules-20-12029]\].

Recently, we have reported on the synthesis of a series of 4-substituted pyridine-3-sulfonamides bearing primary sulfonamide moieties \[[@B16-molecules-20-12029],[@B17-molecules-20-12029]\] as an efficient and selective carbonic anhydrase inhibitors (types **I**--**III**, [Figure 2](#molecules-20-12029-f002){ref-type="fig"}), whereas 4-piperazin-1-yl-pyridine-3-sulfonamides of type **III** ([Figure 2](#molecules-20-12029-f002){ref-type="fig"}) exhibited also moderate anticancer activity \[[@B17-molecules-20-12029]\]. It is also well known that selective hCA inhibitors have a proven ability to limit the growth and restrict metastasis in xenograft models of breast cancer \[[@B18-molecules-20-12029],[@B19-molecules-20-12029]\], and therefore they are considered as novel type of anticancer drugs with novel mechanism of action \[[@B20-molecules-20-12029],[@B21-molecules-20-12029],[@B22-molecules-20-12029],[@B23-molecules-20-12029],[@B24-molecules-20-12029]\].

![General structure of 4-substituted pyridine-3-sulfonamide derivatives.](molecules-20-12029-g002){#molecules-20-12029-f002}

These findings prompted us to explore further series of DSUs possessing 1-(4-substituted pyridine-3-sulfonyl)-3-phenylureas core of type **IV** ([Figure 2](#molecules-20-12029-f002){ref-type="fig"}), and to investigate their anticancer properties.

2. Results and Discussion
=========================

2.1. Chemistry
--------------

The starting 4-substituted pyridine-3-sulfonamides **2**, **4**--**10** were prepared according to the known methods \[[@B16-molecules-20-12029],[@B17-molecules-20-12029]\], while the novel compound 4-\[(5-methyl-1,3,4-thiadiazol-2-yl)thio\]-3-pyridine-sulfonamide (**3**) was synthesized by the reaction of aromatic nucleophilic substitution of chlorine atom of **1** with 5-methyl-1,3,4-thiadiazole-2-thiol, under forcing conditions of elevated pressure and temperature ([Scheme 1](#molecules-20-12029-f003){ref-type="scheme"}).

![Facile synthesis of the starting 4-substituted 3-pyridinesulfonamide derivatives **2**--**10**.](molecules-20-12029-g003){#molecules-20-12029-f003}

The desired, 4-substituted *N*-(phenylcarbamoyl)pyridine-3-sulfonamides **11**--**27** were obtained by treatment for 24 h of primary sulfonamides **2**--**10** with the appropriate aryl isocyanates (*i.e.*, phenyl isocyanate, 4-chlorophenyl isocyanate or 3,4-dichlorophenyl isocyanate) in dry acetone at room temperature in the presence of anhydrous potassium carbonate ([Scheme 2](#molecules-20-12029-f004){ref-type="scheme"}). Then, the initially formed intermediate potassium salts of type **A** were acidified with dilute hydrochloric acid to pH 2, to afford expected diarylsulfonylurea products in moderate to good yields (47%--80%).

![Synthesis of 4-substituted-*N*-(R^2^-phenylcarbamoyl)-3-pyridinesulfonamides **11**--**27**.](molecules-20-12029-g004){#molecules-20-12029-f004}

The final compounds were characterized by IR and NMR spectroscopy as shown in the [Experimental Section](#sec3-molecules-20-12029){ref-type="sec"}. Elemental analyses (C,H,N) were in accordance with the proposed structures. In detail, IR absorption bands corresponding to the stretching vibration of the carbonyl group in -NH(C=O)NH- appeared for compounds **11**--**14** and **24**--**27** in the range of 1716--1732 cm^−1^, and was shifted to 1630--1648 cm^−1^ for compounds **15**--**23** possessing a piperazine ring attached at the 4 position. Inspection of the ^1^H-NMR spectra revealed the characteristic resonance signals of pyridine ring protons appeared as two doublets of H-5 and H-6 at 7.18--7.64 and 8.27--8.96 ppm, respectively, as well as a singlet signal of H-2 at 8.71--9.26 ppm. In turn, the singlet signals attributable to the NH protons of the urea moieties were observed at 8.9--9.4 ppm, whereas a broad singlet of the SO~2~NH proton was found downfield in the wide region of 9.7--13.4 ppm.

2.2. Anticancer Activity
------------------------

Compounds **11**, **12**, **14**--**21** and **24**--**26** were tested *in vitro* at the U.S. National Cancer Institute (Bethesda, MD, USA) at single high concentration of 10 µM against the NCI panel of 60 cell lines derived from nine different human cancer types: leukemia, non-small-cell lung cancer (NSCLC), colon, central nervous system (CNS), melanoma, ovarian, renal, prostate and breast cancer. Inhibition growth percent (IGP) data compared to no-drug control, obtained for each of the cell lines, are shown in [Table 1](#molecules-20-12029-t001){ref-type="table"}.

molecules-20-12029-t001_Table 1

###### 

Inhibition growth percent (IGP \[%\]) for tested compounds (**11**, **12**, **14**--**21**, **24**--**26**) against selected NCI-60 cancer cell lines at single concentration 10^−5^ M.^a^

  Panel               Cell Line    IGP \[%\] of Compound                                                            
  ------------------- ------------ ----------------------- ---- ---- ---- ---- ---- ---- ---- ----- ----- ---- ---- ----
  *Leukemia*          CCRF-CEM     1                       4    27   30   7    --   2    11   \*    85    27   19   --
  K-562               6            67                      --   45   --   7    12   70   20   95    42    72   \*   
  MOLT-4              7            21                      --   27   --   6    5    18   9    85    9     20   8    
  RPMI-8226           \*           \*                      --   70   --   \*   1    7    \*   93    72    10   \*   
  SR                  --           15                      --   16   --   12   --   --   --   95    1     29   19   
  *NSCLC*             HOP-92       \*                      \*   --   53   --   \*   \*   2    \*    131   28   \*   --
  NCI-H522            7            25                      \*   43   \*   8    9    19   5    110   28    12   8    
  *Colon cancer*      HCC-2998     11                      1    \*   1    \*   \*   11   9    2     73    \*   2    \*
  HCT-15              \*           39                      37   \*   31   9    \*   28   \*   41    \*    53   4    
  KM12                \*           43                      \*   25   4    7    --   24   14   89    27    49   \*   
  SW-620              \*           24                      30   10   21   \*   \*   30   \*   82    12    40   \*   
  *CNS cancer*        SF-268       \*                      18   3    1    6    \*   \*   19   6     71    \*   26   \*
  SF-295              11           13                      6    43   13   10   \*   10   --   147   48    \*   1    
  *Melanoma*          LOX IMVI     7                       \-   59   10   56   --   3    47   4     96    10   59   --
  MALME-3M            9            1                       \*   58   \*   3    6    6    5    101   44    2    \*   
  M14                 \*           17                      16   27   17   \*   \*   9    0    77    25    29   \*   
  MDA-MB-435          \*           9                       16   11   12   \*   \*   \*   \*   93    15    23   \*   
  UACC-62             \*           57                      51   33   38   \*   \*   32   \*   73    31    42   10   
  *Ovarian cancer*    OVCAR-3      \*                      \*   \*   42   \*   \*   \*   \*   \*    75    50   \*   \*
  *Renal cancer*      A498         15                      19   33   4    42   5    17   13   12    80    7    6    0
  ACHN                \*           31                      22   25   21   \*   \*   24   \*   93    26    25   \*   
  CAKI-1              2            33                      29   \*   28   11   \*   23   \*   65    5     17   2    
  UO-31               12           18                      17   27   19   9    5    21   10   110   20    29   16   
  *Prostate cancer*   PC-3         11                      6    14   54   17   \*   6    21   16    101   51   12   \*
  DU-145              \*           16                      5    \*   7    \*   \*   18   \*   67    1     32   \*   
  *Breast cancer*     MDA-MB-468   \*                      7    --   59   --   3    \*   \*   \*    109   57   \*   \*
  T-47D               2            20                      21   33   17   6    10   27   9    92    26    18   7    

^a^ Data obtained from NCI-60 DTP human tumor cell line screening \[[@B25-molecules-20-12029],[@B26-molecules-20-12029],[@B27-molecules-20-12029],[@B28-molecules-20-12029],[@B29-molecules-20-12029]\], \* IGP ≤ 0%; -- not tested.

The most important conclusion based on this preliminary anticancer assay is the finding that substitution patterns of the urea phenyl ring (R^2^), has a crucial impact on the cytotoxic activity potency: (a)All compounds with 4-chlorophenylcarbamoyl (R^2^ = 4-Cl) moieties (**12**, **14**, **16**, **19**, **21** and **25**) are characterized by moderate to high activity with IGP range from 17 to 96% against the common cancer cell lines: leukemia (K-562, MOLT-4), colon cancer (HCT-15 and SW-620,) melanoma (LOX IMVI and UACC-62), and renal cancer (ACHN, CAKI-1) ([Table 1](#molecules-20-12029-t001){ref-type="table"}), as well exhibit high overall activity with the average IGP for the whole panel in the range from 7 to 90%.(b)Apparently the introduction of a second chlorine atom in position 3 of the 4-chloro-phenylcarbamoyl moiety (R^2^ = 3,4-diCl) in compounds **17** and **26** definitely causes a loss of activity. In this case the highest IGP values of 12 and 19% are observed only for the leukemia SR cell line.(c)From among of the compounds with unsubstituted phenylcarbamoyl moieties (R^2^ = H; *i.e.*, **11**, **15**, **18**, **20** and **24**) only compounds **15** and **24** exhibit high antiproliferative activity against certain cell lines: leukemia RPMI-8226 (IGP = 70 and 72%), NSCLC HOP-92 (IGP = 53 and 28%), CNS cancer (IGP = SF-295 43 and 48%), melanoma MALME-3M (IGP = 58 and 44%), ovarian cancer OVCAR-3 (IGP = 42 and 50%), prostate cancer PC-3 (IGP = 54 and 51%) or breast cancer MDA-MB-468 (IGP = 59 and 57%), respectively ([Table 1](#molecules-20-12029-t001){ref-type="table"}). It should be noted that the mentioned cell lines, which are highly susceptible for compounds **15** and **24**, do not exhibit significant sensitivity for their 4-chlorophenylurea (R^2^ = 4-Cl) analogs **16** and **25**.

It was stated that among a series of 4-chlorophenylureas (**12**, **14**, **16**, **19**, **21** and **25**) replacement of the benzylthio moiety (R^1^) at the 4 position of the pyridine ring (compound **12**) by a 5-methyl-1,3,4-thiadiazole-2-thiol group in **14** led to a decrease of the susceptibility of NCI-H522 (from 25 to 0%), KM-12 (from 43 to 0%), however the cell lines CCRF-CEM, HCT-116 remain more sensitive to compound **12** (increase from 0 to 25% and from 0 to 43%, respectively). On the other hand removal of the sulfur atom and introduction of a pyrazole moiety in **25** leads to higher activity towards the majority of cell lines, especially for HCT-15, KM 12, SF-268, UO-31 and DU-145 ([Table 1](#molecules-20-12029-t001){ref-type="table"}).

Additionally, introduction of a chlorine atom in **19** to the phenylpiperazinyl substituent of **16** results in a slight increase of antiproliferative activity towards the NSCLC cell line NCI-H522 (from 0 to 19%), colon cancer HCC-2998 (from 0 to 9%), KM12 (from 4 to 24%), SW-620 (from 21 to 30%), CNS cancer SF-268 (from 6 to 19%), prostate cancer PC-3 (from 17 to 21%), DU-145 (from 7 to 18%) breast cancer T-47D (from 17 to 27%), however it also resulted in loss of activity against renal cancer A498 (from 42 to 13%) melanoma M14 (from 17 to 9%) and MDA-MB-435 (from 12 to 0%) ([Table 1](#molecules-20-12029-t001){ref-type="table"}). Nevertheless introducing of second chlorine atom at position 3 of the 4-chlorophenylpiperazin-1-yl in **21** causes a huge increase of activity since all mentioned lines demonstrate IGPs over 66%. The average IGP for all cell lines reached 90% and furthermore a cytotoxic effect (IGP \> 100%) was observed for sixteen cell lines representing all nine cancer types.

Thus, the most active compound *N*-\[(4-chlorophenyl)carbamoyl\]-4-\[4-(3,4-dichlorophenyl)-piperazin-1-yl\]pyridine-3-sulfonamide (**21**) was further tested at the NCI five-dose assay (in the range of 0.01--100 µM) ([Table 2](#molecules-20-12029-t002){ref-type="table"}). A relatively highest sensitivity to this compound was found for the subpanels of leukemia, colon cancer and melanoma, which the average GI~50~ values range from 13.6 to 14.9 µM (*sulofenur* (NSC-642684) 25.5--37.5 µM \[[@B30-molecules-20-12029]\]).

Thus, the lowest GI~50~ was found for the cell lines of melanoma UACC-62 (1.5 µM) and M14 (8.9 µM), leukemia K-562 (3 µM) and CCRF-CEM (8.2 µM), and colon cancer HCT-15 (6.4 µM) as well as for the renal cancer CAKI-1 (6.28 µM) and UO-31 (9.8 µM) cell lines. Furthermore the GI~50~ values for the most sensitive cell lines (GI~50~ \< 20 µM) for compound **21** are of the same order of magnitude and generally lower than for clinically tested *sulofenur* ([Table 2](#molecules-20-12029-t002){ref-type="table"}).

molecules-20-12029-t002_Table 2

###### 

Anticancer *in vitro* data for compound **21** for the most sensitive cell lines (GI~50~ \< 20 µM) ^a^, and comparative data for *sulofenur* (NSC-642684) ^b^ \[[@B30-molecules-20-12029]\].

  Panel               Cell line    21      Sulofenur ^b^                           
  ------------------- ------------ ------- --------------- ------- ------- ------- -------
  *Leukemia*          CCRF-CEM     8.2     43.6            \>100   29.8    \>100   \>100
  K-562               3.0          \>100   \>100           10.2    77.1    \>100   
  MOLT-4              19.9         68.1    \>100           26.4    98.2    \>100   
  RPMI-8226           14.7         54.2    \>100           24.4    85.7    \>100   
  SR                  11.8         51.6    \>100           57.0    \>100   \>100   
  *NSCLC*             A-549/ATCC   14.7    62.8            \>100   32.7    97.7    \>100
  HOP-62              18.8         43.5    \>100           32.2    \>100   \>100   
  NCI-H226            13.4         57.9    \>100           37.9    77.8    \>100   
  NCI-H23             19.9         51.9    \>100           28.1    56.0    90.8    
  NCI-H322M           18.3         \>100   \>100           34.2    95.5    \>100   
  NCI-H460            17.2         69.4    \>100           38.3    100     \>100   
  NCI-H522            14.1         49.4    \>100           27.9    94.2    \>100   
  *Colon cancer*      COLO 205     16.8    33.0            65.0    29.8    60.8    90.2
  HCC-2998            15.5         31.6    64.3            31.6    77.6    98.4    
  HCT-116             15.1         34.4    78.2            26.2    67.3    85.1    
  HCT-15              6.4          68.3    \>100           35.6    90.2    \>100   
  HT29                15.9         45.7    \>100           61.1    \>100   \>100   
  KM12                13.0         \>100   \>100           36.1    98.9    \>100   
  SW-620              14.4         \>100   \>100           35.3    \>100   \>100   
  *CNS cancer*        SF-295       12.2    37.9            \>100   46.7    \>100   \>100
  SF-539              13.1         29.0    64.4            28.3    69.2    \>100   
  SNB-19              19.1         57.6    \>100           40.9    \>100   \>100   
  U251                13.0         36.5    \>100           30.7    77.4    \>100   
  *Melanoma*          M14          8.9     53.4            \>100   37.8    97.5    \>100
  MDA-MB-435          18.9         \>100   \>100           17.6    48.3    \>100   
  SK-MEL-5            10.9         36.7    \>100           26.8    74.0    98.2    
  UACC-62             1.5          15.5    \>100           23.9    84.7    \>100   
  *Ovarian cancer*    IGROV1       16.3    68.1            \>100   12.3    94.4    \>100
  OVCAR-3             16.6         36.7    81.1            24.3    73.8    \>100   
  OVCAR-8             18.6         \>100   \>100           40.8    \>100   \>100   
  NCI/ADR-RES         18.4         \>100   \>100           --      --      --      
  *Renal cancer*      786-0        16.1    43.7            \>100   35.3    \>100   \>100
  A498                15.2         63.1    \>100           45.0    \>100   \>100   
  ACHN                11.6         \>100   \>100           29.4    \>100   \>100   
  CAKI-1              6.3          \>100   \>100           42.8    \>100   \>100   
  SN12C               18.4         \>100   \>100           39.2    \>100   \>100   
  UO-31               9.8          27.3    75.0            25.1    76.4    \>100   
  *Prostate cancer*   PC-3         14.4    71.1            \>100   19.0    47.2    \>100
  DU-145              17.3         55.7    \>100           24.0    92.0    \>100   
  *Breast cancer*     MCF7         19.7    97.4            \>100   24.1    81.8    \>100
  MDA-MB-231/ATCC     14.6         63.3    \>100           --      --      --      
  BT-549              16.1         44.7    \>100           32.6    \>100   \>100   
  T-47D               13.9         87.6    \>100           16.4    74.6    \>100   
  MDA-MB-468          18.9         \>100   \>100           --      --      --      

^a^ Data obtained from NCI-60 DTP human tumor cell line screening \[[@B25-molecules-20-12029],[@B26-molecules-20-12029],[@B27-molecules-20-12029],[@B28-molecules-20-12029],[@B29-molecules-20-12029]\]; ^b^ Sulofenur (NSC-642684): NCI cancer screen; September 2014 \[30\]; ^c^ GI~50~: molar concentration \[µM\] that inhibits 50% net cell growth; ^d^ TGI: molar concentration \[µM\] giving total growth inhibition; ^e^ LC~50~: molar concentration \[µM\] causing 50% net cell death; -- not tested.

3. Experimental Section {#sec3-molecules-20-12029}
=======================

3.1. General Procedures
-----------------------

The following instruments and parameters were used: melting points Boetius HMK apparatus; IR spectra: KBr pellets, 400--4000 cm^−1^ Thermo Mattson Satellite FTIR spectrophotometer; ^1^H- and ^13^C-NMR: Varian Gemini 200 apparatus at 200 MHz (^1^H-NMR) and 50 MHz (^13^C-NMR), Varian Unity 500 Plus apparatus at 500 MHz (^1^H-NMR) and 125 MHz (^13^C-NMR); chemical shifts are expressed in parts per million (ppm) relative to TMS as an internal standard. Elemental analyses were performed on PerkinElmer 2400 Series II CHN Elemental Analyzer, and they were in agreement with the theoretical values within ±0.4% range. The starting 4-chloro-3-pyridinesulfonamide (**1**) was commercially available (Alfa Aesar, Karlsruhe, Germany), while 4-substituted 3-pyridinesulfonamide **2**, **4**--**10** were obtained according to methods described previously: 4-benzylthio-3-pyridinesulfonamie (**2**) \[[@B16-molecules-20-12029]\], 4-(4-substituted-piperazin-1-yl)-3-pyridinesulfonamides **4**--**8** \[[@B17-molecules-20-12029]\], and 4-(1*H*-pyrazol-1-yl)-3-pyridine-sulfonamides **9**, **10** \[[@B17-molecules-20-12029]\].

3.2. Synthesis
--------------

### 3.2.1. Procedure for the Preparation of 4-\[(5-Methyl-1,3,4-thiadiazol-2-yl)thio\]-3-pyridinesulfonamide (**3**)

In a closed glass pressure tube, a mixture of 4-chloro-3-pyridinesulfonamide (1.92 g, 10 mmol) and 5-methyl-1,3,4-thiadiazole-2-thiol (1.57 g, 12 mmol) in dry acetonitrile (16.5 mL) was stirred at room temperature for 2 h and then at 100 °C for 24 h. The precipitate of the hydrochloride was collected by filtration, washed with acetonitrile (3 × 2 mL) and dried, then suspended in water (8 mL) and slowly adjusted to pH 8 with 1% solution of NaOH. After stirring at room temperature for 3 h, the precipitate was filtered off, washed with water (2 × 1 mL), and dried. Yield 2.49 g (86%); mp 132--135 °C; IR (KBr) ν~max~ 3546, 3344 (NH), 1572 (C=C), 1330, 1163 (SO~2~) cm^−1^; ^1^H-NMR (DMSO-*d*~6~, 200 MHz) δ: 2.83 (s, 3H, CH~3~); 7.09 (d, 1H, H-5 pyrid.); 8.00 (s, 2H, NH~2~); 8.56 (d, 1H, H-6 pyrid.); 8.95 (s, 1H, H-2 pyrid.) ppm; anal. C 33.32, H 2.80, N 19.43% calcd. for C~8~H~8~N~4~O~2~S~3~ C 33.02, H 2.84, N 19.33%.

### 3.2.2. General Procedure for the Preparation of 4-Substituted-*N*-(R^2^-phenylcarbamoyl)-3-pyridine-sulfonamides

A mixture of 4-substituted-3-pyridinesulfonamide **2**--**10** (1 mmol), the appropriate phenyl isocyanate (1.2 mmol) and anhydrous potassium carbonate (0.14 g, 1 mmol) in dry acetone (15 mL) was stirred at room temperature for 24 h. The precipitate containing potassium salt of type **A** ([Scheme 2](#molecules-20-12029-f004){ref-type="scheme"}) and inorganic salts was collected by filtration and washed with acetone (2 × 5 mL). The solid thus obtained was suspended in water (5 mL), slowly acidified with 4% hydrochloric acid to pH 2, and stirred overnight. The precipitate was filtered off washed with water (2 × 2 mL), and dried. In this manner the following compounds were obtained:

*4-(Benzylthio)-N-(phenylcarbamoyl)-3-pyridinesulfonamide* (**11**). Starting from 4-benzylthio-3-pyridinesulfonamide (**2**, 0.28 g), and phenyl isocyanate (0.14 g), the title compound **11** was obtained (0.32 g, 80%): mp 198--201 °C; IR (KBr) ν~max~ 3369 (NH), 3081 (C~Ar~-H) 2928, 2853 (C-H), 1727 (C=O), 1600, 1579, 1547 (C=C, C=N), 1350, 1160 (SO~2~) cm^−1^; ^1^H-NMR (DMSO-*d*~6~, 200 MHz) δ 4.51 (s, 2H, CH~2~), 7.03 (t, 1H, H-4ʹ Ph), 7.18--7.34 (m, 7H, H~Ar~), 7.47 (m, 2H, H~Ar~), 7.64 (d, *J* = 5.5 Hz, 1H, H-5 pyrid.), 8.58 (d, *J* = 5.5 Hz, 1H, H-6 pyrid.), 8.71 (s, 1H, H-2 pyrid.), 8.91 (s, 1H, NH), 11.0 (br.s, 1H, NH) ppm; ^13^C-NMR (DMSO-*d*~6~, 125 MHz) δ 35.52, 119.47, 121.45, 124.06, 128.31, 129.29, 129.61, 129.87, 131.89, 135.62, 138.43, 149.58, 149.67, 150.95, 152.89 ppm; anal. C 57.12, H 4.29, N 10.52% calcd for C~19~H~17~N~3~O~3~S~2~ C 56.77, H 4.26, N 10.48%.

*4-(Benzylthio)-N-\[(4-chlorophenyl)carbamoyl\]-3-pyridinesulfonamide* (**12**). Starting from 4-benzyl-thio-3-pyridinesulfonamide (**2**, 0.28 g), and 4-chlorophenyl isocyanate (0.18 g), the title compound **12** was obtained (0.25 g, 58%): mp 204--207 °C; IR (KBr) ν~max~ 3391 (NH), 3107 (C~Ar~-H) 2851 (C-H), 1725 (C=O), 1599, 1581, 1539, 1494 (C=C, C=N), 1347, 1153 (SO~2~) cm^−1^; ^1^H-NMR (DMSO-*d*~6~, 200 MHz) δ 4.50 (s, 2H, CH~2~), 7.24 (m, 3H, H~Ar~), 7.33 (s, 4H, H~Ar~), 7.46 (m, 2H, H~Ar~), 7.64 (d, *J* = 5.0 Hz, 1H, H-5 pyrid.), 8.58 (d, *J* = 5.0 Hz, 1H, H-6 pyrid.), 8.85 (s, 1H, H-2 pyrid.), 8.90 (s, 1H, NH), ppm; ^13^C-NMR (DMSO-*d*~6~, 125 MHz) δ 35.52, 121.13, 121.47, 127.57, 128.32, 129.28, 129.43, 129.89, 131.98, 135.61, 137.53, 149.85, 150.74, 152.68 ppm; anal. C 52.59, H 3.72, N 9.68% calcd for C~19~H~16~ClN~3~O~3~S~2~ C 52.21, H 3.60, N 9.78%.

*4-(Benzylthio)-N-\[(3,4-dichlorophenyl)carbamoyl\]-3-pyridinesulfonamide* (**13**). Starting from 4-benzylthio-3-pyridinesulfonamide (**2**, 0.28 g), and 3,4-dichlorophenylisocyanate (0.23 g), the title compound **13** was obtained (0.27 g, 57%): mp 205--208 °C; IR (KBr) ν~max~ 3377 (NH), 3093 (C~Ar~-H), 2924, 2852 (C-H), 1732 (C=O), 1599, 1578, 1532, 1477 (C=C, C=N), 1352, 1155 (SO2) cm^−1^; ^1^H-NMR (DMSO-*d*~6~, 200 MHz) δ 4.50 (s, 2H, CH~2~), 7.24--7.30 (m, 4H, H~Ar~), 7.44--7.52 (m. 3H, H~Ar~), 7.66--7.68 (m, 2H, H~Ar~, H-5 pyrid~.~), 8.58 (d, 1H, H-6 pyrid.), 8.89 (s, 1H, H-2 pyrid.), 9.03 (s, 1H, NH), ppm; ^13^C-NMR (DMSO-*d*~6~, 50 MHz) δ 35.20, 119.32, 120.27, 121.15, 124.83, 127.90, 128.87, 129.49, 130.91, 131.34, 132.13, 135.20, 138.62, 149.71, 150.11, 150.32, 151.49 ppm; anal. C 48.73, H 3.23, N 8.97% calcd for C~19~H~15~Cl~2~N~3~O~3~S~2~ C 48.17, H 3.00, N 8.85%.

*N-\[(4-Chlorophenyl)carbamoyl\]-4-\[(5-methyl-1,3,4-thiadiazol-2-yl)thio\]-3-pyridinesulfonamide* (**14**). Starting from 4-\[(5-methyl-1,3,4-thiadiazol-2-yl)thio\]-3-pyridinesulfonamide (**3**, 0.29 g), and 4-chloro- phenyl isocyanate (0.18 g), the title compound **14** was obtained (0.28 g, 63%): mp 167--171 °C; IR (KBr) ν~max~ 3297, 3201 (NH), 3076 (C~Ar~-H), 2924, 2855 (C-H), 1716 (C=O), 1610, 1547, 1492 (C=C, C=N), 1350, 1159 (SO~2~) cm^−1^; ^1^H-NMR (DMSO-*d*~6~, 200 MHz) δ 2.80 (s, 3H, CH~3~), 7.18 (d, 1H, H-5 pyrid.), 7.30--7.39 (m, 4H, Ph), 8.63 (d, 1H, H-6 pyrid.), 9.07 (s, 2H, H-2 pyrid. NH), 8.90 (s, 1H, NH), ppm; ^13^C-NMR (DMSO-*d*~6~, 125 MHz) δ 16.47, 121.36, 123.44, 127.60, 129.39, 133.28, 137.61, 145.94, 151.21, 153.96, 157.83, 172.56 ppm; anal. C 40.77, H 2.74, N 15.85% calcd for C~15~H~12~ClN~5~O~3~S~3~ C 40.65, H 2.60, N 16.08%.

*N-(Phenylcarbamoyl)-4-(4-phenylpiperazin-1-yl)-3-pyridinesulfonamide* (**15**). Starting from 4-(4-phenylpiperazin-1-yl)-3-pyridinesulfonamide (**4**, 0.32 g), and phenyl isocyanate (0.14 g), the title compound **15** was obtained (0.32 g, 73%): mp 154--156 °C; IR (KBr) ν~max~ 3466 (NH), 3059 (C~Ar~-H), 2826 (C-H), 1640 (C=O), 1599, 1524, 1504 (C=C, C=N), 1314 1138 (SO~2~) cm^−1^; ^1^H-NMR (DMSO-*d*~6~, 200 MHz) δ 3.33 (s, 4H, 2 × CH~2~), 3.82 (s, 4H, 2 × CH~2~), 6.77--7.06 (m, 4H, H~Ar~), 7.12--7.40 (m, 7H, H~Ar~, H-5 pyrid.), 8.39 (d, 1H, H-6 pyrid.), 8.77 (s, 1H, H-2 pyrid.), 8.92 (s, 1H, NH), 12.10 (br.s, 1H, NH), ppm; ^13^C-NMR (DMSO-*d*~6~, 50 MHz) δ 48.14, 51.06, 114.35, 115.68, 118.31, 119.34, 121.61, 128.72, 129.15, 129.29, 140.59, 150.82, 156,69 ppm; anal. C 60.39, H 5.30, N 16.01%. calcd for C~22~H~23~N~5~O~3~S, C 60.26, H 5.36, N 15.68%.

*N-\[(4-Chlorophenyl)carbamoyl\]-4-(4-phenylpiperazin-1-yl)-3-pyridinesulfonamide* (**16**). Starting from 4-(4-phenylpiperazin-1-yl)-3-pyridinesulfonamide (**4**, 0.32 g), and 4-chlorophenylisocyanate (0.18 g), the title compound **16** was obtained (0.27 g, 56%): mp 145--149 °C; IR (KBr) ν~max~ 3478, 3290 (NH), 3070 (C~Ar~-H), 2836 (C-H), 1641 (C=O), 1603, 1519, (C=C, C=N), 1320, 1133 (SO~2~) cm^−1^; ^1^H-NMR (DMSO-*d*~6~, 200 MHz) δ 3.30 (s, 4H, 2 × CH~2~), 3.96 (s, 4H, 2 × CH~2~), 6.78 (t, 1H, H-4 Ph), 6.94 (d, 2H, H-2,6 Ph), 7.14--7.31 (m, 5H, H~Ar~ and H-5 pyrid~.~), 7.44 (d, 2H, H-2ʹ,6ʹ Ph), 8.32 (d, 1H, H-6 pyrid.), 8.89 (s, 1H, H-2 pyrid.), 8.95 (s, 1H, NH), 13.0 (br.s, 1H, NH), ppm; ^13^C-NMR (DMSO-*d*~6~, 125 MHz) δ 48.57, 51.11, 116.09, 119.81, 128.83, 129.53, 129.71, 151.12, 156.82 ppm; anal. C 55.99, H 4.70, N 14.84%. calcd for C~22~H~22~ClN~5~O~3~S, C 55.78, H 4,96, N 14.71%.

*N-\[(3,4-Dichlorophenyl)carbamoyl\]-4-(4-phenylpiperazin-1-yl)-3-pyridinesulfonamide* (**17**). Starting from 4-(4-phenylpiperazin-1-yl)-3-pyridinesulfonamide (**4**, 0.32 g), and 3,4-dichlorophenyl isocyanate (0.23 g), the title compound **17** was obtained (0.24 g, 47%): mp 172--175 °C; IR (KBr) ν~max~ 3425 (NH), 3062 (C~Ar~-H), 2919, 2855 (C-H), 1630 (C=O), 1599, 1577, 1540, 1506 (C=C, C=N), 1371, 1140 (SO~2~) cm^−1^; ^1^H-NMR (DMSO-*d*~6~, 200 MHz) δ 3.29 (s, 4H, 2 × CH~2~), 4.02 (s, 4H, 2 × CH~2~), 6.79 (t, 1H, H-4 Ph), 6.93 (d, 2H, H-2,6 Ph), 7.18--7.32 (m, 5H, H~Ar~ and H-5 pyrid.), 7.85 (s, 1H, H-2ʹ Ph), 8.27 (d, 1H, H-6 pyrid.), 8.88 (s, 1H, H-2 pyrid.), 9.12 (s, 1H, NH), 13.4 (br.s, 1H, NH), ppm; ^13^C-NMR (DMSO-*d*~6~, 125 MHz) δ 48.58, 50.89, 113.65, 116.10, 118.16, 118.95, 119.83, 121.83, 129.47, 129.71, 130.74, 131.24, 142.68, 146.01, 151.08, 156.64 ppm; anal. C 52.18, H 4.18, N 13.83%. calcd for C~22~H~21~Cl~2~N~5~O~3~S, C 51.78, H 4.05, N 13.86%.

*4-\[4-(4-Chlorophenyl)piperazin-1-yl\]-N-(phenylcarbamoyl)-3-pyridinesulfonamide* (**18**). Starting from 4-\[4-(4-chlorophenyl)piperazin-1-yl\]-3-pyridinesulfonamide (**4**, 0.35 g), and phenyl isocyanate (0.14 g), the title compound **18** was obtained (0.36 g, 76%): mp 177--181 °C; IR (KBr) ν~max~ 3404, 3278 (NH), 3083 (C~Ar~-H), 2923, 2855 (C-H), 1648 (C=O), 1650 1598, 1496 (C=C, C=N), 1311 1128 (SO~2~) cm^−1^; ^1^H-NMR (DMSO-*d*~6~, 200 MHz) δ 3.34 (s, 4H, 2 × CH~2~), 3.81 (s, 4H, 2 × CH~2~), 6.86 (t, 1H, H-4ʹ Ph), 6.98 (d, *J* = 8.9 Hz, 2H, H-2,6 Ph), 7.16 (t, 2H, H-3ʹ5ʹ Ph), 7.26 (d, *J* = 8.9 Hz, 2H, H-3,5 Ph), 7.31 (d, 1H H-5 pyrid.), 7.38 (d, 2H, H-2ʹ,6ʹ Ph), 8.40 (d, 1H, H-6 pyrid.), 8.77 (s, 1H, H-2 pyrid.), 8.92 (s, 1H, NH), ppm; ^13^C-NMR (DMSO-*d*~6~, 125 MHz) δ 48.32, 51.21, 117.52, 118.64, 123.22, 129.11, 129.37, 129.61, 150.02, 157.06 ppm; anal. C 55.99, H 4.70, N 14.84%. calcd for C~22~H~22~ClN~5~O~3~S, C 55.59, H 4.65, N 14.87%.

*N-\[(4-Chlorophenyl)carbamoyl\]-4-\[4-(4-chlorophenyl)piperazin-1-yl\]pyridine-3-sulfonamide* (**19**). Starting from 4-\[4-(4-chlorophenyl)piperazin-1-yl\]-3-pyridinesulfonamide (**5**, 0.35 g), and 4-chloro- phenyl isocyanate (0.18 g), the title compound **19** was obtained (0.28 g, 56%): mp 178--182 °C; IR (KBr) ν~max~ 3427, 3180 (NH), 3050 (C~Ar~-H), 2920, 2854 (C-H), 1642 (C=O), 1626, 1583, 1540, 1497 (C=C, C=N), 1278, 1153 (SO~2~) cm^−1^; ^1^H-NMR (DMSO-*d*~6~, 200 MHz) δ 3.32 (s, 4H, 2 × CH~2~), 3.95 (s, 4H, 2 × CH~2~), 6.96 (d, 2H, H-2,6 Ph), 7.17 (d, 2H, H-3,5 Phʹ), 7.23--7.31 (m, 3H, H-3,5 Ph and H-5 pyrid.), 7.44 (d, 2H, H-2,6 Phʹ), 8.33 (d, 1H, H-6 pyrid.), 8.90 (s, 1H, H-2 pyrid.), 8.93 (s, 1H, NH), ppm; anal. C 52.18, H 4.18, N 13.83%. calcd for C~22~H~21~Cl~2~N~5~O~3~S, C 52.38, H 3.98, N 13.71%.

*4-\[4-(3,4-Dichlorophenyl)piperazin-1-yl\]-N-(phenylcarbamoyl)-3-pyridinesulfonamide* (**20**). Starting from 4-\[4-(3,4-dichlorophenyl)piperazin-1-yl\]-3-pyridinesulfonamide (**6**, 0.39 g), and phenyl isocyanate (0.14 g), the title compound **20** was obtained (0.40 g, 80%): mp 177--180 °C; IR (KBr) ν~max~ 3443 (NH), 3058 (C~Ar~-H), 2837 (C-H), 1639 (C=O), 1595, 1526, 1510, 1485 (C=C, C=N), 1314, 1141 (SO~2~) cm^−1^; ^1^H-NMR (DMSO-*d*~6~, 200 MHz) δ 3.39 (s, 4H, 2 × CH~2~), 3.79 (s, 4H, 2 × CH~2~), 6.86 (t, 1H, H-4ʹ Ph), 6.96 (dd, *J~ortho~* = 8.2 Hz, *J~meta~* = 2.2 Hz, 1H, H-6 3,4-diClPh), 7.16 (m, 3H, H-5 3,4-diClPh and H-3,5 Ph), 7.30 (d,h 1H, H-5 pyrid.), 7.36--7.44 (m, 3H, H-2,6 Ph and H-2,3 4-diClPh), 8.40 (d, 1H, H-6 pyrid.), 8.77 (s, 1H, H-2 pyrid.), 8.91 (s, 1H, NH), ppm; anal. C 52.18, H 4.18, N 13.83%. calcd for C~22~H~21~Cl~2~N~5~O~3~S, C 52.51, H 4.11, N 13.81%.

*N-\[(4-Chlorophenyl)carbamoyl\]-4-\[4-(3,4-dichlorophenyl)piperazin-1-yl\]pyridine-3-sulfonamide* (**21**). Starting from 4-\[4-(3,4-dichlorophenyl)piperazin-1-yl\]-3-pyridinesulfonamide (**6**, 0.39 g), and 4-chlorophenyl isocyanate (0.18 g), the title compound **21** was obtained (0.35 g, 65%): mp 164--168 °C; IR (KBr) ν~max~ 3469 (NH), 3095 (C~Ar~-H), 2925, 2837 (C-H), 1641 (C=O), 1591, 1525, 1489 (C=C, C=N), 1306. 1141 (SO~2~) cm^−1^; ^1^H-NMR (DMSO-*d*~6~, 200 MHz) δ 3.38 (s, 4H, 2 × CH~2~), 3.93 (s, 4H, 2 × CH~2~), 6.94 (dd, 1H, H-6 3,4-diClPh), 7.17 (m, 3H, H-5 3,4-diClPh and H-3,5 Ph), 7.28 (d, 1H, H-5 pyrid.), 7.38--7.46 (m, 3H, H-2,6 Ph and H-2 3,4-diClPh), 8.33 (d, 1H, H-6 pyrid.), 8.89 (s, 1H, H-2 pyrid.), 8.92 (s, 1H, NH), ppm; ^13^C-NMR (DMSO-*d*~6~, 50 MHz) δ 47.32, 50.33, 113.71, 113.75, 115.44, 116.42, 119.47, 119.99, 124.43, 128.42, 129.28, 130.78, 131.82, 140.32, 150.41, 156.49 ppm. anal. C 48.86, H 3.73, N 12.95%. calcd. for C~22~H~20~Cl~3~N~5~O~3~S, C 48.82, H 3.70, N 12.81%.

*N-\[(4-Chlorophenyl)carbamoyl\]-4-\[4-(2,5-dimethylphenyl)piperazin-1-yl\]-3-pyridinesulfonamide* (**22**). Starting from 4-\[4-(2,5-dimethylphenyl)piperazin-1-yl\]-3-pyridinesulfonamide (**7**, 0.35 g), and 4-chlorophenyl isocyanate (0.18 g), the title compound **22** was obtained (0.36 g, 72%): mp 171--174 °C; IR (KBr) ν~max~ 3302 (NH), 3023 (C~Ar~-H), 2945, 2918, 2857 (C-H), 1642 (C=O), 1516 (C=C, C=N), 1320, 1129 (SO~2~) cm^−1^; ^1^H-NMR (DMSO-*d*~6~, 200 MHz) δ 2.24 (s, 6H, 2 × CH~3~), 2.96 (br.s, 4H, 2 × CH~2~), 3.93 (br.s, 4H, 2 × CH~2~), 6.78 (d, 1H, H-4 Ph), 6.86 (s. 1H, H-6 Ph), 7.06 (d, 1H, H-3 Ph), 7.17 (d, 2H, H-3,5 Ph) 7.30 (d, 1H, H-5 pyrid.), 7.47 (d, 2H, H-2,6 Ph), 8.33 (d, 1H, H-6 pyrid.), 8.89 (s, 1H, H-2 pyrid.), 8.97 (s, 1H, NH), ppm; ^13^C-NMR (DMSO-*d*~6~, 125 MHz) δ 17.84, 21.48, 51.83, 51.93, 114.17, 115.86, 119.66, 120.46, 124.45, 128.77, 129.24, 130.32, 131.33, 136.27, 141.13, 146.81, 151.24, 156.94, 157.63 ppm; anal. C 57.65, H 5.24, N 14.01%. calcd for C~24~H~26~ClN~5~O~3~S, C 57.21, H 5.44, N 14.07%.

*N-\[(4-Chlorophenyl)carbamoyl\]-4-\[4-(pyridin-2-yl)piperazin-1-yl\]-3-pyridinesulfonamide* (**23**). Starting from 4-\[4-(pyridin-2-yl)piperazin-1-yl\]-3-pyridinesulfonamide (**8**, 0.32 g), and 4-chlorophenyl isocyanate (0.18 g), the title compound **23** was obtained (0.30 g, 64%): mp 187--193 °C; IR (KBr) ν~max~ 3307 (NH), 3073 (C~Ar~-H), 2923, 2854 (C-H), 1638 (C=O), 1609, 1593, 1505, (C=C, C=N), 1315, 1149 (SO~2~) cm^−1^; ^1^H-NMR (DMSO-*d*~6~, 200 MHz) δ 3.67 (s, 4H, 2 × CH~2~), 3.76 (s, 4H, 2 × CH~2~), 6.66 (t, 1H, H-5′ pyrid.), 6.85 (d, 1H, H-3′ pyrid.), 7.13 (m, 3H, H-3,5 Ph, H-5 pyrid), 7.46 (d, 2H, H-2,6 Ph), 7.56 (t, 1H, H-4′ pyrid.), 8.13 (d, 1H, H-6′ pyrid.), 8.29 (d, 1H, H-6 pyrid.), 8.81 (s, 1H, H-2 pyrid.), 8.91 (s, 1H, NH), ppm; ^13^C-NMR (DMSO-*d*~6~, 125 MHz) δ 45.01, 50.73, 107.79, 113.70, 113.76, 119.61, 124.16, 128.70, 130.79, 138.30, 141.43, 145.69, 148.25, 149.24, 156.08, 158.07, 159.38 ppm; anal. C 53.33, H 4.48, N 17.77%. calcd for C~21~H~21~ClN~6~O~3~S, C 52.44, H 4.19, N 17.67%.

*N-(Phenylcarbamoyl)-4-(3,4,5-trimethyl-1H-pyrazol-1-yl)-3-pyridinesulfonamide* (**24**). Starting from 4-(3,4,5-trimethyl-1*H*-pyrazol-1-yl)-3-pyridinesulfonamide (**9**, 0.27 g), and phenyl isocyanate (0.14 g), the title compound **24** was obtained (0.33 g, 87%): mp 161--164 °C; IR (KBr) ν~max~ 3254, 3199 (NH), 3079, 3018 (C~Ar~-H), 2927, 2860 (C-H), 1730 (C=O), 1583, 1499 (C=C, C=N), 1363, 1350, 1170 (SO~2~) cm^−1^; ^1^H-NMR (DMSO-*d*~6~, 200 MHz) δ 1.93 (s, 3H, CH~3~), 2.05 (s, 3H, CH~3~), 2.17 (s, 3H, CH~3~), 7.04 (t, 1H, H-4 Ph), 7.28 (m, 4H, Ph), 7.57 (d, *J* = 5.2 Hz, 1H H-5 pyrid.), 8.96 (d, *J* = 5.2 Hz, 1H, H-6 pyrid.), 9.08 (s, 1H, H-2 pyrid.), 9.27 (s, 1H, NH), 9.7 (br.s, 1H, NH), ppm; ^13^C-NMR (DMSO-*d*~6~, 125 MHz) δ 8.56, 10.61, 12.64, 114.15, 119.43, 124.07, 124.21, 129.65, 132.08, 138.48, 144.97, 149.67, 150.12, 152.88, 155.93 ppm; anal. C 56.09, H 4.97, N 18.17%. calcd for C~18~H~19~N~5~O~3~S, C 55.78, H 4.89, N 18.18%.

*N-\[(4-Chlorophenyl)carbamoyl\]-4-(3,4,5-trimethyl-1H-pyrazol-1-yl)-3-pyridinesulfonamide* (**25**). Starting from 4-(3,4,5-trimethyl-1*H*-pyrazol-1-yl)-3-pyridinesulfonamide (**9**, 0.27 g), and 4-chloro- phenyl isocyanate (0.18 g), the title compound **25** was obtained (0.31 g, 75%): mp 178--182 °C; IR (KBr) ν~max~ 3247, 3186 (NH), 3010, 3035 (C~Ar~-H), 2992, 2862 (C-H), 1727 (C=O), 1588, 1552, 1496 (C=C, C=N), 1384, 1363, 1170 (SO~2~) cm^−1^; ^1^H-NMR (DMSO-*d*~6~, 200 MHz) δ 1.93 (s, 3H, CH~3~), 2.05 (s, 3H, CH~3~), 2.16 (s, 3H, CH~3~), 7.35 (s, 4H, Ph), 7.57 (d, 1H H-5 pyrid.), 8.96 (d, 1H, H-6 pyrid.), 9.21 (s, 1H, H-2 pyrid.), 9.26 (s, 1H, NH), ppm; ^13^C-NMR (DMSO-*d*~6~, 50 MHz) δ 8.13, 10.19, 12.21, 113.75, 120.69, 123.83, 127.29, 129.11, 131.64, 137.07, 138.09, 144.56, 149.28, 149.72, 152.40, 155.57 ppm; anal. C 51.49, H 4.32, N 16.68%. calcd for C~18~H~18~ClN~5~O~3~S, C 51.22, H 4.20, N 16.57%.

*N-\[(3,4-Dichlorophenyl)carbamoyl\]-4-(3,4,5-trimethyl-1H-pyrazol-1-yl)-3-pyridinesulfonamide* (**26**). Starting from 4-(3,4,5-trimethyl-1*H*-pyrazol-1-yl)-3-pyridinesulfonamide (**9**, 0.27 g), and 3,4-dichloro-phenyl isocyanate (0.23 g), the title compound **26** was obtained (0.25 g, 55%): mp 163--166 °C; IR (KBr) ν~max~ 3324 (NH), 3104 (C~Ar~-H), 2924, 2856 (C-H), 1727 (C=O), 1599, 1581, 1477 (C=C, C=N), 1381 1169 (SO~2~) cm^−1^; ^1^H-NMR (DMSO-*d*~6~, 200 MHz) δ 1.92 (s, 3H, CH~3~), 2.04 (s, 3H, CH~3~), 2.14 (s, 3H, CH~3~), 7.25 (dd, 1H, H-6 Ph), 7.55 (m, 2H, H-5 Ph, H-5 pyrid.), 7.69 (d, 1H H-2 Ph), 8.96 (d, 1H, H-6 pyrid.), 9.26 (s, 1H, H-2 pyrid.), 9.40 (s, 1H, NH), ppm; ^13^C-NMR (DMSO-*d*~6~, 125 MHz) δ 8.55, 10.60, 12.64, 114.16, 119.69, 120.63, 124.29, 125.50, 131.48, 131.85, 132.12, 138.51, 138.78, 144.96, 149.97, 150.13, 152.75, 156.00 ppm; anal. C 47.58, H 3.77, N 15.41% calcd for C~18~H~17~Cl~2~N~5~O~3~S, C 47.45, H 3.81, N 15.38%.

*4-(4-Butyl-3,5-dimethyl-1H-pyrazol-1-yl)-N-\[(4-chlorophenyl)carbamoyl\]-3-pyridinesulfonamide* (**27**). Starting from 4-(4-butyl-3,5-dimethyl-1*H*-pyrazol-1-yl)-3-pyridinesulfonamide (**10**, 0.31 g), and 4-chlorophenyl isocyanate (0.18 g), the title compound **27** was obtained (0.35 g, 76%): m.p. (EtOAc/Et~2~O). 138--142 °C ; IR (KBr) ν~max~ 3344 (NH), 3127, (C~Ar~-H), 2947, 2865 (C-H), 1726 (C=O), 1602, 1579, 1541, 1495 (C=C, C=N), 1385, 1164 (SO~2~) cm^−1^; ^1^H-NMR (DMSO-*d*~6~, 200 MHz) δ 0.90 (t, 3H, CH~3~), 1.36 (m, 4H, 2 × CH~2~), 2.07 (s, 3H, CH~3~), 2.19 (s, 3H, CH~3~), 2.36 (t, 2H, CH~2~), 7.36 (s, 4H, Ph), 7.60 (d, 1H H-5 pyrid.), 8.96 (d, 1H, H-6 pyrid.), 9.25 (s, 1H, H-2 pyrid.), 9.27 (s, 1H, NH), ppm; ^13^C-NMR (DMSO-*d*~6~, 125 MHz) δ 10.61, 12.68, 14.55, 22.46, 23.22, 32.85, 119.09, 121.04, 124.19, 127.66, 129.51, 132.13, 137.50, 138.48, 144.91, 149.77, 149.79, 152.80, 155.88 ppm; anal. C 54.60, H 5.24, N 15.16% calcd for C~21~H~24~ClN~5~O~3~S, C 54.21, H 5.16, N 14.99%.

3.3. In Vitro Anticancer Screening
----------------------------------

Antitumor evaluation of compounds **11**, **12**, **14**--**21** and **24**--**26** was performed at the National Cancer Institute according to NCI-60 DTP Human Tumor Cell Line Screen procedure \[[@B25-molecules-20-12029],[@B26-molecules-20-12029],[@B27-molecules-20-12029],[@B28-molecules-20-12029],[@B29-molecules-20-12029]\].

4. Conclusions
==============

We have obtained a novel series of 4-substituted *N*-(R^2^-phenylcarbamoyl)-3-pyridinesulfonamide derivatives **11**--**27** by the reaction of 4-substituted pyridine-3-sulfonamides **2**--**10** with aryl isocyanates in the presence of potassium carbonate. The compounds **11**, **12**, **14**--**21** and **24**--**26** have been screened *in vitro* for their anticancer activity at the U.S. National Cancer Institute. We found that many of the investigated compounds exhibited structure-dependent moderate or weak anticancer activity. Considering the structure-activity relationships, we conclude that in general the presence of a 4-chlorophenylcarbamoyl moiety attached to the sulfonamide functionality exerts in most cases a favorable influence on anticancer activity and selectivity of the tested diarylsulfonylurea derivatives **12**, **14**, **16**, **19**, **21** and **25**. Thus, the most active compound, *N*-\[(4-chlorophenyl)carbamoyl\]-4-\[4-(3,4-dichlorophenyl)piperazin-1-yl\]pyridine-3-sulfonamide (**21**) exhibited a good activity profile and selectivity toward the subpanels of either leukemia and colon cancer, or melanoma, with average GI~50~ values ranging from 13.6 to 14.9 µM, and could be considered as a lead compound for further optimization.
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